MétaCan
Menu
Back to cohort

S-15-3: COST-EFFECTIVENESS OF A FULL SCOPE OF PHARMACIST CARE FOR HYPERTENSION IN AUSTRALIA

2023· article· en· W4315785293 on OpenAlexaffabout
Aletta E. Schutte, Markus P. Schlaich, Karissa Johnston, Carlo A. Marra, Ross T. Tsuyuki

Bibliographic record

VenueJournal of Hypertension · 2023
Typearticle
Languageen
FieldMedicine
TopicPharmaceutical Practices and Patient Outcomes
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsMedicinePharmacistBlood pressurePharmacoeconomicsQuality of life (healthcare)Cost effectivenessStroke (engine)Emergency medicineHealth careIntensive care medicineFramingham Heart StudyPopulationQuality-adjusted life yearFramingham Risk ScoreDiseaseInternal medicinePharmacyFamily medicineNursingEnvironmental health

Abstract

fetched live from OpenAlex

Hypertension is the single most important cause of premature morbidity and mortality in the world. Over half of all heart disease and stroke are attributable to hypertension, which is associated with approximately 10% of direct medical costs globally. Clinical trial evidence has conclusively demonstrated that pharmacist care, including patient education, consultation, and/or prescribing, significantly reduces blood pressure, including a Canadian randomised trial, RxACTION, which demonstrated an 18.3 mmHg reduction in systolic blood pressure (SBP) with pharmacist prescribing and care. Objective: To evaluate the economic impact of pharmacist management of hypertension in an Australian setting. Methods: A Markov cost effectiveness model was developed to extrapolate potential differences in long-term cardiovascular and renal disease outcomes, using Framingham risk equations and other published risk equations. We assumed an absolute reduction of systolic blood pressure of 18.3 mmHg (from the RxACTION trial). The model incorporated health outcomes, costs, and quality of life to estimate an overall incremental cost effectiveness ratio. Costs considered included direct medical costs as well as the costs associated with implementing the pharmacist intervention strategy. Results: For a SBP reduction of 18.3 mmHg, the estimated impact is 0.22 fewer cardiovascular events per person, and, discounted at 5% per year: 0.2 additional life years, 0.3 additional quality-adjusted life years, and $AU 5,348 cost savings over a lifetime per person. As such, pharmacist care in hypertension is economically dominant, i.e., both more effective and cost saving compared to usual care. At the population level, it has been reported that 34% of Australian adults have hypertension, of whom 68% are not optimally controlled. If 50% of poorly controlled hypertensives could access a full scope of pharmacist care, it is estimated that this would result in 2.1 million life years saved, and a cost saving of $AU 31.1 billion over a 30-year time horizon. Across a range of one way and probabilistic sensitivity analyses of key parameters and assumptions, pharmacist intervention remained both effective and cost saving, indicating robustness of the model. Conclusion: Pharmacist care, including prescribing, when added to usual care by general practitioners, would lead to better BP outcomes and a net cost saving of over $AU 30 billion. If implemented, this would have important public health implications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.103
Threshold uncertainty score0.204

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.021
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0010.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.341
GPT teacher head0.459
Teacher spread0.117 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueJournal of HypertensionSame topicPharmaceutical Practices and Patient OutcomesFrench-language works237,207